NCT07159126View on ClinicalTrials.gov

A Study of DS3610a in Participants With Advanced Solid Tumor

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

February 1, 2031

Conditions

Solid TumorsMetastatic Solid Tumors

Interventions

DRUG

DS3610a

Participants will receive DS3610a at the target dose. Treatment will continue until radiographic disease progression, as determined by the investigator, or until another reason for discontinuation of trial intervention occurs.